nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—CYP1A1—prostate cancer	0.36	1	CbGaD
Dicyclomine—CYP1A1—Flutamide—prostate cancer	0.145	0.468	CbGbCtD
Dicyclomine—CYP1A1—Estrone—prostate cancer	0.105	0.338	CbGbCtD
Dicyclomine—CYP1A1—Estradiol—prostate cancer	0.0602	0.194	CbGbCtD
Dicyclomine—CHRM3—ureter—prostate cancer	0.0163	0.553	CbGeAlD
Dicyclomine—CHRM2—prostate gland—prostate cancer	0.00233	0.0791	CbGeAlD
Dicyclomine—CHRM1—prostate gland—prostate cancer	0.00212	0.072	CbGeAlD
Dicyclomine—CHRM3—prostate gland—prostate cancer	0.0019	0.0645	CbGeAlD
Dicyclomine—CHRM3—renal system—prostate cancer	0.00129	0.0439	CbGeAlD
Dicyclomine—CHRM3—urethra—prostate cancer	0.00127	0.0432	CbGeAlD
Dicyclomine—CYP1A1—epithelium—prostate cancer	0.00104	0.0355	CbGeAlD
Dicyclomine—CYP1A1—renal system—prostate cancer	0.000968	0.0329	CbGeAlD
Dicyclomine—CYP1A1—urethra—prostate cancer	0.000951	0.0323	CbGeAlD
Dicyclomine—CHRM3—testis—prostate cancer	0.000835	0.0284	CbGeAlD
Dicyclomine—CYP1A1—lymph node—prostate cancer	0.000453	0.0154	CbGeAlD
Dicyclomine—Anorexia—Etoposide—prostate cancer	0.000124	0.000603	CcSEcCtD
Dicyclomine—Hypersensitivity—Estradiol—prostate cancer	0.000123	0.000602	CcSEcCtD
Dicyclomine—Abdominal pain—Mitoxantrone—prostate cancer	0.000123	0.000601	CcSEcCtD
Dicyclomine—Eye disorder—Prednisone—prostate cancer	0.000122	0.000597	CcSEcCtD
Dicyclomine—Muscular weakness—Doxorubicin—prostate cancer	0.000121	0.000589	CcSEcCtD
Dicyclomine—Vision blurred—Capecitabine—prostate cancer	0.00012	0.000588	CcSEcCtD
Dicyclomine—Asthenia—Estradiol—prostate cancer	0.00012	0.000586	CcSEcCtD
Dicyclomine—Abdominal distension—Doxorubicin—prostate cancer	0.000119	0.000581	CcSEcCtD
Dicyclomine—Ill-defined disorder—Capecitabine—prostate cancer	0.000119	0.000579	CcSEcCtD
Dicyclomine—Syncope—Docetaxel—prostate cancer	0.000118	0.000578	CcSEcCtD
Dicyclomine—Pruritus—Estradiol—prostate cancer	0.000118	0.000578	CcSEcCtD
Dicyclomine—Immune system disorder—Prednisone—prostate cancer	0.000118	0.000577	CcSEcCtD
Dicyclomine—Palpitations—Docetaxel—prostate cancer	0.000117	0.000569	CcSEcCtD
Dicyclomine—Paraesthesia—Etoposide—prostate cancer	0.000116	0.000568	CcSEcCtD
Dicyclomine—Loss of consciousness—Docetaxel—prostate cancer	0.000116	0.000566	CcSEcCtD
Dicyclomine—Dyspnoea—Etoposide—prostate cancer	0.000116	0.000564	CcSEcCtD
Dicyclomine—Malaise—Capecitabine—prostate cancer	0.000115	0.000563	CcSEcCtD
Dicyclomine—Somnolence—Etoposide—prostate cancer	0.000115	0.000563	CcSEcCtD
Dicyclomine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000115	0.000561	CcSEcCtD
Dicyclomine—Syncope—Capecitabine—prostate cancer	0.000115	0.00056	CcSEcCtD
Dicyclomine—Mental disorder—Prednisone—prostate cancer	0.000115	0.000559	CcSEcCtD
Dicyclomine—Hypertension—Docetaxel—prostate cancer	0.000114	0.000556	CcSEcCtD
Dicyclomine—Drowsiness—Epirubicin—prostate cancer	0.000114	0.000556	CcSEcCtD
Dicyclomine—Erythema—Prednisone—prostate cancer	0.000114	0.000556	CcSEcCtD
Dicyclomine—Palpitations—Capecitabine—prostate cancer	0.000113	0.000551	CcSEcCtD
Dicyclomine—Decreased appetite—Etoposide—prostate cancer	0.000113	0.00055	CcSEcCtD
Dicyclomine—Loss of consciousness—Capecitabine—prostate cancer	0.000112	0.000548	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Etoposide—prostate cancer	0.000112	0.000546	CcSEcCtD
Dicyclomine—Asthenia—Mitoxantrone—prostate cancer	0.000112	0.000546	CcSEcCtD
Dicyclomine—Fatigue—Etoposide—prostate cancer	0.000112	0.000546	CcSEcCtD
Dicyclomine—Pain—Etoposide—prostate cancer	0.000111	0.000541	CcSEcCtD
Dicyclomine—Constipation—Etoposide—prostate cancer	0.000111	0.000541	CcSEcCtD
Dicyclomine—Dizziness—Estradiol—prostate cancer	0.000111	0.00054	CcSEcCtD
Dicyclomine—Hypertension—Capecitabine—prostate cancer	0.00011	0.000539	CcSEcCtD
Dicyclomine—Dry mouth—Docetaxel—prostate cancer	0.00011	0.000537	CcSEcCtD
Dicyclomine—Confusional state—Docetaxel—prostate cancer	0.000109	0.00053	CcSEcCtD
Dicyclomine—Anaphylactic shock—Docetaxel—prostate cancer	0.000108	0.000526	CcSEcCtD
Dicyclomine—Oedema—Docetaxel—prostate cancer	0.000108	0.000526	CcSEcCtD
Dicyclomine—Discomfort—Capecitabine—prostate cancer	0.000108	0.000525	CcSEcCtD
Dicyclomine—Vision blurred—Prednisone—prostate cancer	0.000107	0.000524	CcSEcCtD
Dicyclomine—Feeling abnormal—Etoposide—prostate cancer	0.000107	0.000521	CcSEcCtD
Dicyclomine—Dry mouth—Capecitabine—prostate cancer	0.000106	0.000519	CcSEcCtD
Dicyclomine—Vomiting—Estradiol—prostate cancer	0.000106	0.000519	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Etoposide—prostate cancer	0.000106	0.000517	CcSEcCtD
Dicyclomine—Shock—Docetaxel—prostate cancer	0.000106	0.000517	CcSEcCtD
Dicyclomine—Nervous system disorder—Docetaxel—prostate cancer	0.000106	0.000516	CcSEcCtD
Dicyclomine—Ill-defined disorder—Prednisone—prostate cancer	0.000106	0.000516	CcSEcCtD
Dicyclomine—Rash—Estradiol—prostate cancer	0.000105	0.000515	CcSEcCtD
Dicyclomine—Drowsiness—Doxorubicin—prostate cancer	0.000105	0.000515	CcSEcCtD
Dicyclomine—Dermatitis—Estradiol—prostate cancer	0.000105	0.000514	CcSEcCtD
Dicyclomine—Confusional state—Capecitabine—prostate cancer	0.000105	0.000513	CcSEcCtD
Dicyclomine—Tachycardia—Docetaxel—prostate cancer	0.000105	0.000513	CcSEcCtD
Dicyclomine—Headache—Estradiol—prostate cancer	0.000105	0.000512	CcSEcCtD
Dicyclomine—Agitation—Prednisone—prostate cancer	0.000105	0.000511	CcSEcCtD
Dicyclomine—Oedema—Capecitabine—prostate cancer	0.000104	0.000509	CcSEcCtD
Dicyclomine—Angioedema—Prednisone—prostate cancer	0.000104	0.000508	CcSEcCtD
Dicyclomine—Urticaria—Etoposide—prostate cancer	0.000103	0.000503	CcSEcCtD
Dicyclomine—Anorexia—Docetaxel—prostate cancer	0.000103	0.000501	CcSEcCtD
Dicyclomine—Malaise—Prednisone—prostate cancer	0.000103	0.000501	CcSEcCtD
Dicyclomine—Shock—Capecitabine—prostate cancer	0.000103	0.000501	CcSEcCtD
Dicyclomine—Abdominal pain—Etoposide—prostate cancer	0.000102	0.0005	CcSEcCtD
Dicyclomine—Nervous system disorder—Capecitabine—prostate cancer	0.000102	0.000499	CcSEcCtD
Dicyclomine—Syncope—Prednisone—prostate cancer	0.000102	0.000498	CcSEcCtD
Dicyclomine—Tachycardia—Capecitabine—prostate cancer	0.000102	0.000497	CcSEcCtD
Dicyclomine—Hypoaesthesia—Epirubicin—prostate cancer	0.000102	0.000497	CcSEcCtD
Dicyclomine—Loss of consciousness—Prednisone—prostate cancer	0.0001	0.000488	CcSEcCtD
Dicyclomine—Anorexia—Capecitabine—prostate cancer	9.94e-05	0.000485	CcSEcCtD
Dicyclomine—Nausea—Estradiol—prostate cancer	9.94e-05	0.000485	CcSEcCtD
Dicyclomine—Vomiting—Mitoxantrone—prostate cancer	9.91e-05	0.000484	CcSEcCtD
Dicyclomine—Hypertension—Prednisone—prostate cancer	9.83e-05	0.00048	CcSEcCtD
Dicyclomine—Rash—Mitoxantrone—prostate cancer	9.83e-05	0.00048	CcSEcCtD
Dicyclomine—Dermatitis—Mitoxantrone—prostate cancer	9.82e-05	0.000479	CcSEcCtD
Dicyclomine—Headache—Mitoxantrone—prostate cancer	9.76e-05	0.000477	CcSEcCtD
Dicyclomine—Insomnia—Docetaxel—prostate cancer	9.75e-05	0.000476	CcSEcCtD
Dicyclomine—Paraesthesia—Docetaxel—prostate cancer	9.68e-05	0.000472	CcSEcCtD
Dicyclomine—Dyspnoea—Docetaxel—prostate cancer	9.61e-05	0.000469	CcSEcCtD
Dicyclomine—Somnolence—Docetaxel—prostate cancer	9.58e-05	0.000468	CcSEcCtD
Dicyclomine—Discomfort—Prednisone—prostate cancer	9.58e-05	0.000467	CcSEcCtD
Dicyclomine—Eye disorder—Epirubicin—prostate cancer	9.56e-05	0.000467	CcSEcCtD
Dicyclomine—Hypersensitivity—Etoposide—prostate cancer	9.55e-05	0.000466	CcSEcCtD
Dicyclomine—Cardiac disorder—Epirubicin—prostate cancer	9.49e-05	0.000463	CcSEcCtD
Dicyclomine—Dyspepsia—Docetaxel—prostate cancer	9.48e-05	0.000463	CcSEcCtD
Dicyclomine—Insomnia—Capecitabine—prostate cancer	9.44e-05	0.000461	CcSEcCtD
Dicyclomine—Hypoaesthesia—Doxorubicin—prostate cancer	9.42e-05	0.00046	CcSEcCtD
Dicyclomine—Paraesthesia—Capecitabine—prostate cancer	9.37e-05	0.000457	CcSEcCtD
Dicyclomine—Decreased appetite—Docetaxel—prostate cancer	9.37e-05	0.000457	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Docetaxel—prostate cancer	9.3e-05	0.000454	CcSEcCtD
Dicyclomine—Asthenia—Etoposide—prostate cancer	9.3e-05	0.000454	CcSEcCtD
Dicyclomine—Dyspnoea—Capecitabine—prostate cancer	9.3e-05	0.000454	CcSEcCtD
Dicyclomine—Anaphylactic shock—Prednisone—prostate cancer	9.29e-05	0.000454	CcSEcCtD
Dicyclomine—Oedema—Prednisone—prostate cancer	9.29e-05	0.000454	CcSEcCtD
Dicyclomine—Fatigue—Docetaxel—prostate cancer	9.29e-05	0.000453	CcSEcCtD
Dicyclomine—Nausea—Mitoxantrone—prostate cancer	9.26e-05	0.000452	CcSEcCtD
Dicyclomine—Immune system disorder—Epirubicin—prostate cancer	9.24e-05	0.000451	CcSEcCtD
Dicyclomine—Mediastinal disorder—Epirubicin—prostate cancer	9.22e-05	0.00045	CcSEcCtD
Dicyclomine—Pain—Docetaxel—prostate cancer	9.21e-05	0.00045	CcSEcCtD
Dicyclomine—Constipation—Docetaxel—prostate cancer	9.21e-05	0.00045	CcSEcCtD
Dicyclomine—Dyspepsia—Capecitabine—prostate cancer	9.18e-05	0.000448	CcSEcCtD
Dicyclomine—Pruritus—Etoposide—prostate cancer	9.17e-05	0.000448	CcSEcCtD
Dicyclomine—Shock—Prednisone—prostate cancer	9.14e-05	0.000446	CcSEcCtD
Dicyclomine—Nervous system disorder—Prednisone—prostate cancer	9.11e-05	0.000445	CcSEcCtD
Dicyclomine—Tachycardia—Prednisone—prostate cancer	9.07e-05	0.000443	CcSEcCtD
Dicyclomine—Decreased appetite—Capecitabine—prostate cancer	9.07e-05	0.000443	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Capecitabine—prostate cancer	9.01e-05	0.00044	CcSEcCtD
Dicyclomine—Fatigue—Capecitabine—prostate cancer	8.99e-05	0.000439	CcSEcCtD
Dicyclomine—Mental disorder—Epirubicin—prostate cancer	8.96e-05	0.000437	CcSEcCtD
Dicyclomine—Constipation—Capecitabine—prostate cancer	8.92e-05	0.000435	CcSEcCtD
Dicyclomine—Pain—Capecitabine—prostate cancer	8.92e-05	0.000435	CcSEcCtD
Dicyclomine—Erythema—Epirubicin—prostate cancer	8.9e-05	0.000435	CcSEcCtD
Dicyclomine—Feeling abnormal—Docetaxel—prostate cancer	8.88e-05	0.000433	CcSEcCtD
Dicyclomine—Anorexia—Prednisone—prostate cancer	8.86e-05	0.000432	CcSEcCtD
Dicyclomine—Eye disorder—Doxorubicin—prostate cancer	8.85e-05	0.000432	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Docetaxel—prostate cancer	8.81e-05	0.00043	CcSEcCtD
Dicyclomine—Cardiac disorder—Doxorubicin—prostate cancer	8.78e-05	0.000429	CcSEcCtD
Dicyclomine—Tension—Epirubicin—prostate cancer	8.74e-05	0.000427	CcSEcCtD
Dicyclomine—Nervousness—Epirubicin—prostate cancer	8.65e-05	0.000422	CcSEcCtD
Dicyclomine—Feeling abnormal—Capecitabine—prostate cancer	8.6e-05	0.00042	CcSEcCtD
Dicyclomine—Dizziness—Etoposide—prostate cancer	8.57e-05	0.000418	CcSEcCtD
Dicyclomine—Immune system disorder—Doxorubicin—prostate cancer	8.55e-05	0.000417	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Capecitabine—prostate cancer	8.53e-05	0.000416	CcSEcCtD
Dicyclomine—Mediastinal disorder—Doxorubicin—prostate cancer	8.53e-05	0.000416	CcSEcCtD
Dicyclomine—Abdominal pain—Docetaxel—prostate cancer	8.52e-05	0.000416	CcSEcCtD
Dicyclomine—Insomnia—Prednisone—prostate cancer	8.4e-05	0.00041	CcSEcCtD
Dicyclomine—Vision blurred—Epirubicin—prostate cancer	8.39e-05	0.00041	CcSEcCtD
Dicyclomine—Paraesthesia—Prednisone—prostate cancer	8.34e-05	0.000407	CcSEcCtD
Dicyclomine—Mental disorder—Doxorubicin—prostate cancer	8.29e-05	0.000405	CcSEcCtD
Dicyclomine—Urticaria—Capecitabine—prostate cancer	8.29e-05	0.000405	CcSEcCtD
Dicyclomine—Ill-defined disorder—Epirubicin—prostate cancer	8.26e-05	0.000403	CcSEcCtD
Dicyclomine—Abdominal pain—Capecitabine—prostate cancer	8.25e-05	0.000403	CcSEcCtD
Dicyclomine—Vomiting—Etoposide—prostate cancer	8.24e-05	0.000402	CcSEcCtD
Dicyclomine—Erythema—Doxorubicin—prostate cancer	8.24e-05	0.000402	CcSEcCtD
Dicyclomine—Agitation—Epirubicin—prostate cancer	8.18e-05	0.000399	CcSEcCtD
Dicyclomine—Dyspepsia—Prednisone—prostate cancer	8.18e-05	0.000399	CcSEcCtD
Dicyclomine—Rash—Etoposide—prostate cancer	8.17e-05	0.000399	CcSEcCtD
Dicyclomine—Dermatitis—Etoposide—prostate cancer	8.17e-05	0.000399	CcSEcCtD
Dicyclomine—Headache—Etoposide—prostate cancer	8.12e-05	0.000396	CcSEcCtD
Dicyclomine—Tension—Doxorubicin—prostate cancer	8.09e-05	0.000395	CcSEcCtD
Dicyclomine—Decreased appetite—Prednisone—prostate cancer	8.08e-05	0.000394	CcSEcCtD
Dicyclomine—Malaise—Epirubicin—prostate cancer	8.03e-05	0.000392	CcSEcCtD
Dicyclomine—Fatigue—Prednisone—prostate cancer	8.01e-05	0.000391	CcSEcCtD
Dicyclomine—Nervousness—Doxorubicin—prostate cancer	8e-05	0.000391	CcSEcCtD
Dicyclomine—Syncope—Epirubicin—prostate cancer	7.99e-05	0.00039	CcSEcCtD
Dicyclomine—Constipation—Prednisone—prostate cancer	7.95e-05	0.000388	CcSEcCtD
Dicyclomine—Hypersensitivity—Docetaxel—prostate cancer	7.94e-05	0.000387	CcSEcCtD
Dicyclomine—Palpitations—Epirubicin—prostate cancer	7.87e-05	0.000384	CcSEcCtD
Dicyclomine—Loss of consciousness—Epirubicin—prostate cancer	7.83e-05	0.000382	CcSEcCtD
Dicyclomine—Vision blurred—Doxorubicin—prostate cancer	7.77e-05	0.000379	CcSEcCtD
Dicyclomine—Asthenia—Docetaxel—prostate cancer	7.73e-05	0.000377	CcSEcCtD
Dicyclomine—Nausea—Etoposide—prostate cancer	7.7e-05	0.000376	CcSEcCtD
Dicyclomine—Hypertension—Epirubicin—prostate cancer	7.69e-05	0.000375	CcSEcCtD
Dicyclomine—Hypersensitivity—Capecitabine—prostate cancer	7.69e-05	0.000375	CcSEcCtD
Dicyclomine—Feeling abnormal—Prednisone—prostate cancer	7.66e-05	0.000374	CcSEcCtD
Dicyclomine—Ill-defined disorder—Doxorubicin—prostate cancer	7.64e-05	0.000373	CcSEcCtD
Dicyclomine—Pruritus—Docetaxel—prostate cancer	7.62e-05	0.000372	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Prednisone—prostate cancer	7.6e-05	0.000371	CcSEcCtD
Dicyclomine—Agitation—Doxorubicin—prostate cancer	7.57e-05	0.00037	CcSEcCtD
Dicyclomine—Discomfort—Epirubicin—prostate cancer	7.49e-05	0.000366	CcSEcCtD
Dicyclomine—Asthenia—Capecitabine—prostate cancer	7.48e-05	0.000365	CcSEcCtD
Dicyclomine—Malaise—Doxorubicin—prostate cancer	7.43e-05	0.000363	CcSEcCtD
Dicyclomine—Dry mouth—Epirubicin—prostate cancer	7.41e-05	0.000362	CcSEcCtD
Dicyclomine—Syncope—Doxorubicin—prostate cancer	7.39e-05	0.000361	CcSEcCtD
Dicyclomine—Urticaria—Prednisone—prostate cancer	7.38e-05	0.00036	CcSEcCtD
Dicyclomine—Pruritus—Capecitabine—prostate cancer	7.38e-05	0.00036	CcSEcCtD
Dicyclomine—Abdominal pain—Prednisone—prostate cancer	7.35e-05	0.000359	CcSEcCtD
Dicyclomine—Confusional state—Epirubicin—prostate cancer	7.33e-05	0.000358	CcSEcCtD
Dicyclomine—Palpitations—Doxorubicin—prostate cancer	7.28e-05	0.000355	CcSEcCtD
Dicyclomine—Anaphylactic shock—Epirubicin—prostate cancer	7.27e-05	0.000355	CcSEcCtD
Dicyclomine—Oedema—Epirubicin—prostate cancer	7.27e-05	0.000355	CcSEcCtD
Dicyclomine—Loss of consciousness—Doxorubicin—prostate cancer	7.24e-05	0.000353	CcSEcCtD
Dicyclomine—Shock—Epirubicin—prostate cancer	7.15e-05	0.000349	CcSEcCtD
Dicyclomine—Nervous system disorder—Epirubicin—prostate cancer	7.13e-05	0.000348	CcSEcCtD
Dicyclomine—Dizziness—Docetaxel—prostate cancer	7.13e-05	0.000348	CcSEcCtD
Dicyclomine—Hypertension—Doxorubicin—prostate cancer	7.11e-05	0.000347	CcSEcCtD
Dicyclomine—Tachycardia—Epirubicin—prostate cancer	7.09e-05	0.000346	CcSEcCtD
Dicyclomine—Discomfort—Doxorubicin—prostate cancer	6.93e-05	0.000338	CcSEcCtD
Dicyclomine—Anorexia—Epirubicin—prostate cancer	6.93e-05	0.000338	CcSEcCtD
Dicyclomine—Dizziness—Capecitabine—prostate cancer	6.9e-05	0.000337	CcSEcCtD
Dicyclomine—Dry mouth—Doxorubicin—prostate cancer	6.86e-05	0.000335	CcSEcCtD
Dicyclomine—Vomiting—Docetaxel—prostate cancer	6.85e-05	0.000334	CcSEcCtD
Dicyclomine—Hypersensitivity—Prednisone—prostate cancer	6.85e-05	0.000334	CcSEcCtD
Dicyclomine—Rash—Docetaxel—prostate cancer	6.79e-05	0.000332	CcSEcCtD
Dicyclomine—Dermatitis—Docetaxel—prostate cancer	6.79e-05	0.000331	CcSEcCtD
Dicyclomine—Confusional state—Doxorubicin—prostate cancer	6.78e-05	0.000331	CcSEcCtD
Dicyclomine—Headache—Docetaxel—prostate cancer	6.75e-05	0.000329	CcSEcCtD
Dicyclomine—Anaphylactic shock—Doxorubicin—prostate cancer	6.72e-05	0.000328	CcSEcCtD
Dicyclomine—Oedema—Doxorubicin—prostate cancer	6.72e-05	0.000328	CcSEcCtD
Dicyclomine—Asthenia—Prednisone—prostate cancer	6.67e-05	0.000325	CcSEcCtD
Dicyclomine—Vomiting—Capecitabine—prostate cancer	6.63e-05	0.000324	CcSEcCtD
Dicyclomine—Shock—Doxorubicin—prostate cancer	6.62e-05	0.000323	CcSEcCtD
Dicyclomine—Nervous system disorder—Doxorubicin—prostate cancer	6.59e-05	0.000322	CcSEcCtD
Dicyclomine—Rash—Capecitabine—prostate cancer	6.58e-05	0.000321	CcSEcCtD
Dicyclomine—Pruritus—Prednisone—prostate cancer	6.57e-05	0.000321	CcSEcCtD
Dicyclomine—Insomnia—Epirubicin—prostate cancer	6.57e-05	0.000321	CcSEcCtD
Dicyclomine—Dermatitis—Capecitabine—prostate cancer	6.57e-05	0.000321	CcSEcCtD
Dicyclomine—Tachycardia—Doxorubicin—prostate cancer	6.56e-05	0.00032	CcSEcCtD
Dicyclomine—Headache—Capecitabine—prostate cancer	6.54e-05	0.000319	CcSEcCtD
Dicyclomine—Paraesthesia—Epirubicin—prostate cancer	6.53e-05	0.000319	CcSEcCtD
Dicyclomine—Dyspnoea—Epirubicin—prostate cancer	6.48e-05	0.000316	CcSEcCtD
Dicyclomine—Somnolence—Epirubicin—prostate cancer	6.46e-05	0.000315	CcSEcCtD
Dicyclomine—Anorexia—Doxorubicin—prostate cancer	6.41e-05	0.000313	CcSEcCtD
Dicyclomine—Nausea—Docetaxel—prostate cancer	6.4e-05	0.000312	CcSEcCtD
Dicyclomine—Dyspepsia—Epirubicin—prostate cancer	6.4e-05	0.000312	CcSEcCtD
Dicyclomine—Decreased appetite—Epirubicin—prostate cancer	6.32e-05	0.000308	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Epirubicin—prostate cancer	6.27e-05	0.000306	CcSEcCtD
Dicyclomine—Fatigue—Epirubicin—prostate cancer	6.27e-05	0.000306	CcSEcCtD
Dicyclomine—Pain—Epirubicin—prostate cancer	6.21e-05	0.000303	CcSEcCtD
Dicyclomine—Constipation—Epirubicin—prostate cancer	6.21e-05	0.000303	CcSEcCtD
Dicyclomine—Nausea—Capecitabine—prostate cancer	6.2e-05	0.000302	CcSEcCtD
Dicyclomine—Dizziness—Prednisone—prostate cancer	6.14e-05	0.0003	CcSEcCtD
Dicyclomine—Insomnia—Doxorubicin—prostate cancer	6.08e-05	0.000297	CcSEcCtD
Dicyclomine—Paraesthesia—Doxorubicin—prostate cancer	6.04e-05	0.000295	CcSEcCtD
Dicyclomine—Dyspnoea—Doxorubicin—prostate cancer	6e-05	0.000293	CcSEcCtD
Dicyclomine—Feeling abnormal—Epirubicin—prostate cancer	5.99e-05	0.000292	CcSEcCtD
Dicyclomine—Somnolence—Doxorubicin—prostate cancer	5.98e-05	0.000292	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Epirubicin—prostate cancer	5.94e-05	0.00029	CcSEcCtD
Dicyclomine—Dyspepsia—Doxorubicin—prostate cancer	5.92e-05	0.000289	CcSEcCtD
Dicyclomine—Vomiting—Prednisone—prostate cancer	5.91e-05	0.000288	CcSEcCtD
Dicyclomine—Rash—Prednisone—prostate cancer	5.86e-05	0.000286	CcSEcCtD
Dicyclomine—Dermatitis—Prednisone—prostate cancer	5.85e-05	0.000286	CcSEcCtD
Dicyclomine—Decreased appetite—Doxorubicin—prostate cancer	5.85e-05	0.000285	CcSEcCtD
Dicyclomine—Headache—Prednisone—prostate cancer	5.82e-05	0.000284	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.81e-05	0.000283	CcSEcCtD
Dicyclomine—Fatigue—Doxorubicin—prostate cancer	5.8e-05	0.000283	CcSEcCtD
Dicyclomine—Urticaria—Epirubicin—prostate cancer	5.77e-05	0.000282	CcSEcCtD
Dicyclomine—Pain—Doxorubicin—prostate cancer	5.75e-05	0.000281	CcSEcCtD
Dicyclomine—Constipation—Doxorubicin—prostate cancer	5.75e-05	0.000281	CcSEcCtD
Dicyclomine—Abdominal pain—Epirubicin—prostate cancer	5.75e-05	0.00028	CcSEcCtD
Dicyclomine—Feeling abnormal—Doxorubicin—prostate cancer	5.54e-05	0.00027	CcSEcCtD
Dicyclomine—Nausea—Prednisone—prostate cancer	5.52e-05	0.000269	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Doxorubicin—prostate cancer	5.5e-05	0.000268	CcSEcCtD
Dicyclomine—Hypersensitivity—Epirubicin—prostate cancer	5.35e-05	0.000261	CcSEcCtD
Dicyclomine—Urticaria—Doxorubicin—prostate cancer	5.34e-05	0.000261	CcSEcCtD
Dicyclomine—Abdominal pain—Doxorubicin—prostate cancer	5.32e-05	0.000259	CcSEcCtD
Dicyclomine—Asthenia—Epirubicin—prostate cancer	5.21e-05	0.000255	CcSEcCtD
Dicyclomine—Pruritus—Epirubicin—prostate cancer	5.14e-05	0.000251	CcSEcCtD
Dicyclomine—Hypersensitivity—Doxorubicin—prostate cancer	4.95e-05	0.000242	CcSEcCtD
Dicyclomine—Asthenia—Doxorubicin—prostate cancer	4.82e-05	0.000235	CcSEcCtD
Dicyclomine—Dizziness—Epirubicin—prostate cancer	4.81e-05	0.000235	CcSEcCtD
Dicyclomine—Pruritus—Doxorubicin—prostate cancer	4.76e-05	0.000232	CcSEcCtD
Dicyclomine—Vomiting—Epirubicin—prostate cancer	4.62e-05	0.000226	CcSEcCtD
Dicyclomine—Rash—Epirubicin—prostate cancer	4.58e-05	0.000224	CcSEcCtD
Dicyclomine—Dermatitis—Epirubicin—prostate cancer	4.58e-05	0.000223	CcSEcCtD
Dicyclomine—Headache—Epirubicin—prostate cancer	4.55e-05	0.000222	CcSEcCtD
Dicyclomine—Dizziness—Doxorubicin—prostate cancer	4.45e-05	0.000217	CcSEcCtD
Dicyclomine—Nausea—Epirubicin—prostate cancer	4.32e-05	0.000211	CcSEcCtD
Dicyclomine—Vomiting—Doxorubicin—prostate cancer	4.28e-05	0.000209	CcSEcCtD
Dicyclomine—Rash—Doxorubicin—prostate cancer	4.24e-05	0.000207	CcSEcCtD
Dicyclomine—Dermatitis—Doxorubicin—prostate cancer	4.24e-05	0.000207	CcSEcCtD
Dicyclomine—Headache—Doxorubicin—prostate cancer	4.21e-05	0.000206	CcSEcCtD
Dicyclomine—Nausea—Doxorubicin—prostate cancer	3.99e-05	0.000195	CcSEcCtD
Dicyclomine—CHRM1—Signaling by GPCR—MAP2K1—prostate cancer	9.84e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—MAP2K1—prostate cancer	9.81e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CD—prostate cancer	9.78e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—VAV3—prostate cancer	9.77e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—JAK2—prostate cancer	9.76e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CD—prostate cancer	9.75e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—VAV3—prostate cancer	9.74e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—MAP2K1—prostate cancer	9.72e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CD—prostate cancer	9.65e-06	0.000101	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—VAV3—prostate cancer	9.64e-06	0.000101	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TGFBR2—prostate cancer	9.63e-06	0.000101	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TGFBR2—prostate cancer	9.6e-06	0.0001	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—RXRA—prostate cancer	9.51e-06	9.94e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TGFBR2—prostate cancer	9.51e-06	9.93e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ITPR1—prostate cancer	9.48e-06	9.9e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ITPR1—prostate cancer	9.45e-06	9.87e-05	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CB—prostate cancer	9.39e-06	9.81e-05	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CB—prostate cancer	9.36e-06	9.78e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ITPR1—prostate cancer	9.36e-06	9.77e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—MTHFR—prostate cancer	9.32e-06	9.74e-05	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CB—prostate cancer	9.27e-06	9.68e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	9.25e-06	9.67e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—COMT—prostate cancer	9.16e-06	9.57e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PPARA—prostate cancer	9.15e-06	9.56e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GSTP1—prostate cancer	9.12e-06	9.53e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IGF1R—prostate cancer	9.06e-06	9.47e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IGF1R—prostate cancer	9.03e-06	9.44e-05	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CXCL8—prostate cancer	9.02e-06	9.42e-05	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CXCL8—prostate cancer	8.99e-06	9.39e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—JAK2—prostate cancer	8.98e-06	9.38e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ITPR1—prostate cancer	8.98e-06	9.38e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—JAK2—prostate cancer	8.95e-06	9.35e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IGF1R—prostate cancer	8.94e-06	9.35e-05	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CXCL8—prostate cancer	8.9e-06	9.3e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—JAK2—prostate cancer	8.86e-06	9.26e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	8.82e-06	9.22e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—LPL—prostate cancer	8.69e-06	9.08e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—LPL—prostate cancer	8.66e-06	9.05e-05	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—IL2—prostate cancer	8.62e-06	9.01e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PDGFRB—prostate cancer	8.61e-06	9e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CAV1—prostate cancer	8.6e-06	8.99e-05	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—IL2—prostate cancer	8.59e-06	8.98e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PDGFRB—prostate cancer	8.58e-06	8.97e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—LPL—prostate cancer	8.58e-06	8.96e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CB—prostate cancer	8.52e-06	8.91e-05	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—IL2—prostate cancer	8.51e-06	8.89e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PDGFRB—prostate cancer	8.5e-06	8.88e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CB—prostate cancer	8.5e-06	8.88e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—TYMS—prostate cancer	8.48e-06	8.86e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CB—prostate cancer	8.41e-06	8.79e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ITGB3—prostate cancer	8.39e-06	8.77e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GSTM1—prostate cancer	8.38e-06	8.76e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ITGB3—prostate cancer	8.36e-06	8.74e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ITGB3—prostate cancer	8.28e-06	8.65e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—LPL—prostate cancer	8.23e-06	8.6e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CXCL8—prostate cancer	8.19e-06	8.56e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CXCL8—prostate cancer	8.17e-06	8.53e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ERBB3—prostate cancer	8.14e-06	8.5e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FGFR2—prostate cancer	8.13e-06	8.49e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ERBB3—prostate cancer	8.11e-06	8.48e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FGFR2—prostate cancer	8.1e-06	8.46e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CXCL8—prostate cancer	8.09e-06	8.45e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ERBB3—prostate cancer	8.03e-06	8.39e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FGFR2—prostate cancer	8.02e-06	8.38e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ERCC2—prostate cancer	7.88e-06	8.23e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CG—prostate cancer	7.83e-06	8.19e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL2—prostate cancer	7.83e-06	8.18e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL2—prostate cancer	7.8e-06	8.15e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TERT—prostate cancer	7.8e-06	8.15e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TERT—prostate cancer	7.78e-06	8.12e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL2—prostate cancer	7.73e-06	8.07e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TERT—prostate cancer	7.7e-06	8.04e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HIF1A—prostate cancer	7.46e-06	7.79e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HIF1A—prostate cancer	7.44e-06	7.77e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—INS—prostate cancer	7.42e-06	7.75e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—MTHFR—prostate cancer	7.41e-06	7.74e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HIF1A—prostate cancer	7.36e-06	7.69e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—LEP—prostate cancer	7.28e-06	7.61e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PPARA—prostate cancer	7.27e-06	7.59e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CREBBP—prostate cancer	7.26e-06	7.59e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—LEP—prostate cancer	7.26e-06	7.58e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CAV1—prostate cancer	7.21e-06	7.54e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CAV1—prostate cancer	7.19e-06	7.51e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—LEP—prostate cancer	7.19e-06	7.51e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KDR—prostate cancer	7.13e-06	7.45e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CAV1—prostate cancer	7.12e-06	7.44e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KDR—prostate cancer	7.11e-06	7.43e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KDR—prostate cancer	7.04e-06	7.36e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ESR1—prostate cancer	6.95e-06	7.26e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ESR1—prostate cancer	6.93e-06	7.24e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CD—prostate cancer	6.89e-06	7.2e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ESR1—prostate cancer	6.86e-06	7.17e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CAV1—prostate cancer	6.83e-06	7.14e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—BAD—prostate cancer	6.79e-06	7.09e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—BAD—prostate cancer	6.76e-06	7.07e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—BAD—prostate cancer	6.7e-06	7e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—APC—prostate cancer	6.57e-06	6.87e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CG—prostate cancer	6.57e-06	6.87e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—APC—prostate cancer	6.55e-06	6.84e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CG—prostate cancer	6.55e-06	6.84e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.53e-06	6.82e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—NOS3—prostate cancer	6.5e-06	6.79e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EGF—prostate cancer	6.5e-06	6.79e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IRS1—prostate cancer	6.5e-06	6.79e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—APC—prostate cancer	6.49e-06	6.78e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CG—prostate cancer	6.49e-06	6.78e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EGF—prostate cancer	6.48e-06	6.77e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IRS1—prostate cancer	6.48e-06	6.77e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EGF—prostate cancer	6.41e-06	6.7e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IRS1—prostate cancer	6.41e-06	6.7e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—GSK3B—prostate cancer	6.31e-06	6.59e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—GSK3B—prostate cancer	6.29e-06	6.57e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—GSK3B—prostate cancer	6.23e-06	6.5e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CG—prostate cancer	6.22e-06	6.5e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—INS—prostate cancer	6.22e-06	6.5e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—INS—prostate cancer	6.2e-06	6.48e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—INS—prostate cancer	6.14e-06	6.42e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CREBBP—prostate cancer	6.09e-06	6.37e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CREBBP—prostate cancer	6.07e-06	6.35e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IGF1—prostate cancer	6.02e-06	6.29e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CREBBP—prostate cancer	6.01e-06	6.28e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CB—prostate cancer	6e-06	6.27e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IGF1—prostate cancer	6e-06	6.27e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—EGFR—prostate cancer	5.99e-06	6.26e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—EGFR—prostate cancer	5.97e-06	6.24e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTGS2—prostate cancer	5.95e-06	6.21e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IGF1—prostate cancer	5.94e-06	6.21e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—EGFR—prostate cancer	5.91e-06	6.18e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—INS—prostate cancer	5.89e-06	6.16e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAP2K1—prostate cancer	5.82e-06	6.08e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAP2K1—prostate cancer	5.8e-06	6.06e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CD—prostate cancer	5.78e-06	6.04e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CREBBP—prostate cancer	5.77e-06	6.03e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CD—prostate cancer	5.76e-06	6.02e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAP2K1—prostate cancer	5.74e-06	6e-05	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CA—prostate cancer	5.72e-06	5.98e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SERPINE1—prostate cancer	5.71e-06	5.97e-05	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CA—prostate cancer	5.7e-06	5.96e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CD—prostate cancer	5.7e-06	5.96e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SERPINE1—prostate cancer	5.7e-06	5.95e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—KRAS—prostate cancer	5.66e-06	5.91e-05	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CA—prostate cancer	5.65e-06	5.9e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SERPINE1—prostate cancer	5.64e-06	5.89e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—KRAS—prostate cancer	5.64e-06	5.89e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—KRAS—prostate cancer	5.58e-06	5.83e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FGF2—prostate cancer	5.53e-06	5.78e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FGF2—prostate cancer	5.51e-06	5.76e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CD—prostate cancer	5.47e-06	5.72e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FGF2—prostate cancer	5.46e-06	5.71e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOS3—prostate cancer	5.46e-06	5.7e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOS3—prostate cancer	5.44e-06	5.68e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOS3—prostate cancer	5.39e-06	5.63e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—JAK2—prostate cancer	5.3e-06	5.54e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—JAK2—prostate cancer	5.29e-06	5.52e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—JAK2—prostate cancer	5.23e-06	5.47e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CA—prostate cancer	5.2e-06	5.43e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTEN—prostate cancer	5.19e-06	5.42e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CA—prostate cancer	5.18e-06	5.41e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MDM2—prostate cancer	5.18e-06	5.41e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—NOS3—prostate cancer	5.17e-06	5.4e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MDM2—prostate cancer	5.16e-06	5.39e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CA—prostate cancer	5.13e-06	5.36e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MDM2—prostate cancer	5.11e-06	5.34e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ERBB2—prostate cancer	5.1e-06	5.33e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ERBB2—prostate cancer	5.09e-06	5.31e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ERBB2—prostate cancer	5.04e-06	5.26e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CB—prostate cancer	5.04e-06	5.26e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CB—prostate cancer	5.02e-06	5.24e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CB—prostate cancer	4.97e-06	5.19e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—EP300—prostate cancer	4.95e-06	5.17e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CXCL8—prostate cancer	4.84e-06	5.06e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CXCL8—prostate cancer	4.82e-06	5.04e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CXCL8—prostate cancer	4.78e-06	4.99e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CB—prostate cancer	4.77e-06	4.98e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CDKN1B—prostate cancer	4.73e-06	4.94e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTGS2—prostate cancer	4.73e-06	4.94e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CDKN1B—prostate cancer	4.71e-06	4.92e-05	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—AKT1—prostate cancer	4.67e-06	4.88e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN1B—prostate cancer	4.67e-06	4.87e-05	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—AKT1—prostate cancer	4.66e-06	4.87e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CASP3—prostate cancer	4.63e-06	4.84e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL2—prostate cancer	4.62e-06	4.83e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CASP3—prostate cancer	4.62e-06	4.82e-05	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—AKT1—prostate cancer	4.61e-06	4.82e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL2—prostate cancer	4.61e-06	4.82e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL6—prostate cancer	4.6e-06	4.81e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL6—prostate cancer	4.59e-06	4.79e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CASP3—prostate cancer	4.57e-06	4.78e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL2—prostate cancer	4.57e-06	4.77e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL6—prostate cancer	4.54e-06	4.75e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCND1—prostate cancer	4.51e-06	4.71e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCND1—prostate cancer	4.49e-06	4.7e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CTNNB1—prostate cancer	4.46e-06	4.66e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCND1—prostate cancer	4.45e-06	4.65e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CTNNB1—prostate cancer	4.45e-06	4.65e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CTNNB1—prostate cancer	4.41e-06	4.6e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MMP9—prostate cancer	4.38e-06	4.57e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MMP9—prostate cancer	4.36e-06	4.56e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	4.36e-06	4.56e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PTEN—prostate cancer	4.35e-06	4.55e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	4.35e-06	4.54e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PTEN—prostate cancer	4.34e-06	4.53e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MMP9—prostate cancer	4.32e-06	4.51e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	4.31e-06	4.5e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PTEN—prostate cancer	4.3e-06	4.49e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—AKT1—prostate cancer	4.25e-06	4.44e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—AKT1—prostate cancer	4.23e-06	4.42e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—AKT1—prostate cancer	4.19e-06	4.38e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EP300—prostate cancer	4.15e-06	4.34e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EP300—prostate cancer	4.14e-06	4.32e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTEN—prostate cancer	4.12e-06	4.31e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EP300—prostate cancer	4.1e-06	4.28e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SRC—prostate cancer	4.04e-06	4.22e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SRC—prostate cancer	4.02e-06	4.2e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SRC—prostate cancer	3.98e-06	4.16e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—VEGFA—prostate cancer	3.93e-06	4.11e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—EP300—prostate cancer	3.93e-06	4.11e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—VEGFA—prostate cancer	3.92e-06	4.09e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—STAT3—prostate cancer	3.89e-06	4.07e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—VEGFA—prostate cancer	3.88e-06	4.05e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—STAT3—prostate cancer	3.88e-06	4.05e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—STAT3—prostate cancer	3.84e-06	4.01e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CA—prostate cancer	3.66e-06	3.82e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MYC—prostate cancer	3.62e-06	3.78e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TGFB1—prostate cancer	3.61e-06	3.77e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MYC—prostate cancer	3.6e-06	3.77e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TGFB1—prostate cancer	3.6e-06	3.76e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MYC—prostate cancer	3.57e-06	3.73e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TGFB1—prostate cancer	3.56e-06	3.72e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EGFR—prostate cancer	3.54e-06	3.7e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EGFR—prostate cancer	3.53e-06	3.68e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EGFR—prostate cancer	3.49e-06	3.65e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KRAS—prostate cancer	3.34e-06	3.49e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KRAS—prostate cancer	3.33e-06	3.48e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KRAS—prostate cancer	3.3e-06	3.45e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	3.07e-06	3.21e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	3.06e-06	3.2e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	3.03e-06	3.17e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—AKT1—prostate cancer	2.99e-06	3.12e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TP53—prostate cancer	2.97e-06	3.1e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TP53—prostate cancer	2.96e-06	3.09e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TP53—prostate cancer	2.93e-06	3.06e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CA—prostate cancer	2.91e-06	3.04e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL6—prostate cancer	2.72e-06	2.84e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL6—prostate cancer	2.71e-06	2.83e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL6—prostate cancer	2.68e-06	2.8e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—AKT1—prostate cancer	2.51e-06	2.62e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—AKT1—prostate cancer	2.5e-06	2.61e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—AKT1—prostate cancer	2.48e-06	2.59e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—AKT1—prostate cancer	2.37e-06	2.48e-05	CbGpPWpGaD
